News
Drug and biotech news
Trade press headlines, FDA announcements, new drug and biologic approvals, and Class I recalls, newest first. Refreshed hourly. Stories open on the publisher's site.
Last checked: Nov 20, 2026Source: BioPharma Dive, STAT (pharma), FDA press releases, FDA MedWatch, Drugs@FDA (new approvals), openFDA (Class I recalls)
All areasOncologyHematology and blood cancersCardiovascular and metabolicNeurologyPsychiatryImmunology and inflammationInfectious disease and vaccinesRespiratoryRare and genetic diseaseKidney and urologyGastroenterology and liverEndocrinology and women's healthOphthalmologyDermatologyPain and anesthesia
2 stories
Tagged Neurology from the headline and teaser, so some stories may be missed or misfiled.
- FDA approvalDrugs@FDANov 13, 2026FDA novel drug approval: Klygefa (Gefurulimab), Alexion Pharm
To treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis Orphan.
- FDA approvalDrugs@FDAOct 15, 2026FDA new use approved: Zilbrysq (Zilucoplan Sodium), Ucb INC
Efficacy supplement 15. Orphan.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.